Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Beam Therapeutics (BEAM) EPS (Basic): 2019-2025

Historic EPS (Basic) for Beam Therapeutics (BEAM) over the last 7 years, with Sep 2025 value amounting to -$1.10.

  • Beam Therapeutics' EPS (Basic) rose 5.98% to -$1.10 in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.43, marking a year-over-year decrease of 180.38%. This contributed to the annual value of -$4.58 for FY2024, which is 166.28% down from last year.
  • Latest data reveals that Beam Therapeutics reported EPS (Basic) of -$1.10 as of Q3 2025, which was down 10.00% from -$1 recorded in Q2 2025.
  • Beam Therapeutics' 5-year EPS (Basic) high stood at $1.91 for Q4 2023, and its period low was -$3.35 during Q1 2021.
  • Moreover, its 3-year median value for EPS (Basic) was -$1.11 (2024), whereas its average is -$0.88.
  • In the last 5 years, Beam Therapeutics' EPS (Basic) crashed by 271.43% in 2022 and then surged by 453.70% in 2023.
  • Over the past 5 years, Beam Therapeutics' EPS (Basic) (Quarterly) stood at -$0.91 in 2021, then skyrocketed by 40.66% to -$0.54 in 2022, then spiked by 453.70% to $1.91 in 2023, then slumped by 157.07% to -$1.09 in 2024, then climbed by 5.98% to -$1.10 in 2025.
  • Its EPS (Basic) was -$1.10 in Q3 2025, compared to -$1 in Q2 2025 and -$1.24 in Q1 2025.